Submission Of New Drug Application For Acute Myeloid Leukemia Treatment "Olutasidenib" In Japan
27/05/2026 07:38
BRIEF-Kissei Pharmaceutical Co Ltd - Submission Of New Drug Application For Acute Myeloid Leukemia Treatment "Olutasidenib" In Japan May 27 (Reuters) - Kissei Pharmaceutical Co Ltd 4547.T:
KISSEI PHARMACEUTICAL CO LTD: SUBMISSION OF NEW DRUG APPLICATION FOR ACUTE MYELOID LEUKEMIA TREATMENT "OLUTASIDENIB" IN JAPAN
Source text: ID:nTSqa8652a
Further company coverage: 4547.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on Kissei Pharmaceutical Co
See all newsAmgen up after EMA recommends revoking marketing authorization for rare-disease drug
Submission Of New Drug Application For Acute Myeloid Leukemia Treatment "Olutasidenib" In Japan
Currently Examining Financial Impact Of Rapid Safety Communication Regarding Tavneos (Generic Name Avacopan)
Advisory: Incorrectly tagged Kissei alert withdrawn
Amgen's rare disease drug linked to deaths, liver injuries in Japan, Kissei reports (updated)